Correlation between immune-related adverse events and therapeutic effects of nivolumab in patients with malignant pleural mesothelioma
Abstract Background Nivolumab is used for the treatment of malignant pleural mesothelioma (MPM). However, immune-related adverse events (irAEs) occur in patients treated with nivolumab. Several studies have reported the correlation between irAEs and therapeutic effects of immune checkpoint inhibitor...
Guardado en:
Autores principales: | Hiroto Yoneda, Hiroshi Nokihara, Atsushi Mitsuhashi, Ryohiko Ozaki, Yohei Yabuki, Hirokazu Ogino, Kenji Otsuka, Yasuhiko Nishioka |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
BMC
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/283e2c804e1e4caca2a024bc86d5df46 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Extended Pleurectomy/Decortication for Malignant Pleural Mesothelioma: Humanitas’s Experience
por: Giuseppe Mangiameli, et al.
Publicado: (2021) -
Diagnostic and Prognostic Utility of the Extracellular Vesicles Subpopulations Present in Pleural Effusion
por: Joman Javadi, et al.
Publicado: (2021) -
MALAT1 promotes malignant pleural mesothelioma by sponging miR-141-3p
por: Wang Pei, et al.
Publicado: (2021) -
Pain management in patients with malignant mesothelioma: challenges and solutions
por: Saunders J, et al.
Publicado: (2019) -
Clinical staging of malignant pleural mesothelioma: current perspectives
por: Bonomi M, et al.
Publicado: (2017)